| Literature DB >> 32930481 |
Armin Welker1, Christian Kersten2, Christin Müller3, Ramakanth Madhugiri3, Collin Zimmer2, Patrick Müller2, Robert Zimmermann2, Stefan Hammerschmidt2, Hannah Maus2, John Ziebuhr3, Christoph Sotriffer1, Tanja Schirmeister2.
Abstract
Inhibition of coronavirus (CoV)-encoded papain-like cysteine proteases (PLpro ) represents an attractive strategy to treat infections by these important human pathogens. Herein we report on structure-activity relationships (SAR) of the noncovalent active-site directed inhibitor (R)-5-amino-2-methyl-N-(1-(naphthalen-1-yl)ethyl) benzamide (2 b), which is known to bind into the S3 and S4 pockets of the SARS-CoV PLpro . Moreover, we report the discovery of isoindolines as a new class of potent PLpro inhibitors. The studies also provide a deeper understanding of the binding modes of this inhibitor class. Importantly, the inhibitors were also confirmed to inhibit SARS-CoV-2 replication in cell culture suggesting that, due to the high structural similarities of the target proteases, inhibitors identified against SARS-CoV PLpro are valuable starting points for the development of new pan-coronaviral inhibitors.Entities:
Keywords: Antiviral agents; Computational chemistry; Drug design; Protease inhibitors; Structure-activity relationships
Year: 2020 PMID: 32930481 DOI: 10.1002/cmdc.202000548
Source DB: PubMed Journal: ChemMedChem ISSN: 1860-7179 Impact factor: 3.466